Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2016 07:00 ET | Source: Curis, Inc

Curis Reports Third Quarter 2016 Financial Results

LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
October 27, 2016 07:00 ET | Source: Curis, Inc

Curis to Release Third Quarter 2016 Financial Results and Hold Conference Call on November 3, 2016

LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
October 11, 2016 07:05 ET | Source: Curis, Inc

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
October 11, 2016 07:00 ET | Source: Curis, Inc

Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

CA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration ...
September 16, 2016 10:26 ET | Source: Curis, Inc

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
September 07, 2016 06:55 ET | Source: Curis, Inc

Aurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under Collaboration Agreement

LEXINGTON, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
August 31, 2016 07:00 ET | Source: Curis, Inc

Curis to Present at Baird’s 2016 Global Healthcare Conference

LEXINGTON, Mass., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
August 04, 2016 07:00 ET | Source: Curis, Inc

Curis Reports Second Quarter 2016 Financial Results

LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
July 28, 2016 07:00 ET | Source: Curis, Inc

Curis to Release Second Quarter 2016 Financial Results and Hold Conference Call on August 4, 2016

LEXINGTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
June 21, 2016 07:00 ET | Source: Curis, Inc

Curis Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints

LEXINGTON, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for...